Gastroententive drug delivery system of ranitidine hydrochloride formulation and in vitro evaluation

AAPS PharmSciTech

Volumn 5, Issue 2, 2004, Pages

  Dave, Brijesh S ^a   Amin, Avani F ^a   Patel, Madhabhai M ^a  

^a GANPAT UNIVERSITY   (India)

Author keywords

Floating drug delivery; Gastroretentive; Ranitidine hydrochloride; Sustained release

Indexed keywords

BICARBONATE; CITRIC ACID; GUAR GUM; HYDROXYPROPYLMETHYLCELLULOSE; RANITIDINE; STEARIC ACID; XANTHAN; HISTAMINE H2 RECEPTOR ANTAGONIST;

ARTICLE; BIOLOGICAL MODEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; FACTORIAL ANALYSIS; HYDROPHOBICITY; IN VITRO STUDY; CHEMISTRY; STOMACH;

CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; HISTAMINE H2 ANTAGONISTS; RANITIDINE; STOMACH;

EID: 23144448318     PISSN: 15309932     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Histamine H2 antagonists. In: Drug Facts and Comparisons. 16th ed. St Louis, MO: Wolters Kluwer Co; 1996:1862-1876.
2. Somade S, Singh K. Comparative evaluation of wet granulation and direct compression methods for preparation of controlled release Ranitidine HCL tablets. Indian J Pharm Sci. 2002;64:285.
3. Lauritsen K. Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases. Clin Pharmacokinet. 1990;19:11-31, 94-125.
4. Grant S. Ranitidine: an updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer and other allied diseases. Drugs. 1989;37:801-870.
5. Basit A, Lacey L. Colonic metabolism of ranitidine: implications for its delivery and absorption. Int J Pharm. 2001;227(1-2):157-165.
6. Coffin M, Parr A. Ranitidine solid dosage form. US Patent 5 407 687. April 18, 1995.
7. Singh B, Kim K. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Control Release. 2000;63:235-259.
8. Chawla G, Bansal A. A means to address regional variability in intestinal drug absorption. Pharm Tech. 2003;27:50-68.
9. Rosa M, Zia H, Rhodes T. Dosing and testing in-vitro of a bioadhesive and floating drug delivery system for oral application. Int J Pharm. 1994;105:65-70.
10. Korsemeyer R, Gurny R, Peppas N. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm. 1983;15:25-35.
11. Wagner JG. Interpretation of percent dissolved-time plots derived from in vitro testing of conventional tablets and capsules. J Pharm Sci. 1969;58:1253-1257.
12. Gibaldi M, Feldman S. Establishment of sink conditions in dissolution rate determinations: theoretical considerations and application to nondisintegrating dosage forms. J Pharm Sci. 1967;56:1238-1242.
13. Higuchi T. Rate of release of medicaments from ointment bases containing drugs in suspension. J Pharm Sci. 1961;50:874-875.
14. Higuchi T. Mechanism of sustained-action medication: theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci. 1963;52:1145-1149.
15. Cobby J, Mayersohn M, Walker GC. Influence of shape factors on kinetics of drug release from matrix tablets. II. Experimental. J Pharm Sci. 1974;63:732-737.
16. Hixson AW, Crowell JH. Dependence of reaction velocity upon surface and agitation. Ind Eng Chem. 1931;23:923-931.
17. Peppas NA. Analysis of Fickian and non-Fickian drug release from polymers. Pharm Acta Helv. 1985;60:110-111.
18. Harland RS, Gazzaniga A, Sangalli ME, Colombo P, Peppas NA. Drug/polymer matrix swelling and dissolution. Pharm Res. 1988;5:488-494.
19. Langenbucher F. Linearization of dissolution rate curves by the Weibull distribution. J Pharm Pharmacol. 1988;24:979-981.
20. Goldsmith JA, Randall N, Ross SD. On methods of expressing dissolution rate data. J Pharm Pharmacol. 1978;30:347-349.
21. Romero P, Costa JB, Chulia D. Statistical optimization of a controlled release formulation obtained by a double compression process: application of a Hadamard matrix and a factorial design. In: Wells JI, Rubinstein MH, Horwood E, eds. Pharmaceutical Technology, Controlled Drug Release. Vol 2. New York, NY: Ellis Harwood; 1991:44-58.
22. Vudathala GK, Rogers JA. Dissolution of fludrocortisone from phospholipid coprecipitates. J Pharm Sci. 1992;81(3):282-286.
23. Bamba M, Puisieusx F. Release mechanisms in gel forming sustained release preparation. Int J Pharm. 1979;2:307-315.
24. Whitehead L, Fell J, Collett J, Sharma H, Smith A. Floating dosage forms: an in vivo study demonstrating prolonged gastric retention. J Control Release. 1998;55:3-12.
25. Eyjolfsson R. Ranitidine HCl: tablet film coating acidity and discoloration. Drug Dev Ind Pharm. 2000;26:693-694.
26. Guidance for Industry SUPAC-MR. Modified Release Solid Oral Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls; In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation. Available at: http://www.fda.gov/cder/guidance/index.htm.
27. Moore J, Flanner H. Mathematical comparison of dissolution profiles. Pharm Tech. 1996;20:64-74.